沙丁胺醇联合布地奈德雾化吸入对慢性阻塞性肺疾病的临床治疗效果分析
|
摘要
目的探究慢性阻塞性肺疾病患者接受沙丁胺醇、布地奈德联合雾化吸入的临床疗效。方法该次选择2015年5月—2018年12月该院收治慢性阻塞性肺疾病患者136例为研究对象,参照抽签结果分为观察组与对照组,对照组患者单纯接受沙丁胺醇雾化吸入治疗,观察组患者采取沙丁胺醇联合布地奈德雾化吸入治疗,对比治疗总疗效,记录并分析各组患者临床症状缓解情况差异,计算不良反应发生率。结果观察组患者治疗总疗效明显高于对照组(P<0.05),同时观察组患者哮鸣音消失时间(4.35±0.24)d、咳嗽症状缓解时间(2.98±1.01)d、住院总时间(8.44±0.36)d均明显短于对照组(t=23.41、7.89、25.15,P<0.05)。观察组患者药物不良反应发生概率与对照组相比,差异无统计学意义(P>0.05)。结论慢性阻塞性肺疾病患者接受沙丁胺醇联合布地奈德雾化吸入治疗效果更佳,可改善患者咳嗽等症状,缩短患者住院时长,且用药后不良反应少,值得推广应用。
Objective To investigate the clinical efficacy of salbutamol and budesonide combined with aerosol inhalation in patients with chronic obstructive pulmonary disease. Methods 136 cases of patients with chronic obstructive pulmonary disease admitted to our hospital from May 2015 to December 2018 were selected as subjects. According to the results of the drafting, these patients were divided into observation group and control group. The control group received salbutamol aerosol inhalation treatment. Patients in the observation group were treated with salbutamol combined with budesonide inhalation, and the total efficacy was compared. The differences in clinical symptom relief between the groups were recorded and analyzed, and the incidence of adverse reactions was calculated. Re-sults The total therapeutic effect of the observation group was significantly higher than that of the control group( P<0.05). At the same time, the wheezing time disappeared(4.35±0.24) d, the cough symptom relief time(2.98±1.01) d, and the total hospital stay(8.44±0.36)d were significantly shorter than the control group(t=23.41, 7.89, 25.15, P<0.05). There was no statistically significant difference in the incidence of adverse drug reactions between the observation group and the control group( P>0.05). Conclusion Patients with chronic obstructive pulmonary disease receiving salbutamol combined with budesonide inhalation have better effects, can improve symptoms such as cough, shorten the length of hospital stay, and have fewer adverse reactions after administration. It is worthy of popularization and application.
Objective To investigate the clinical efficacy of salbutamol and budesonide combined with aerosol inhalation in patients with chronic obstructive pulmonary disease. Methods 136 cases of patients with chronic obstructive pulmonary disease admitted to our hospital from May 2015 to December 2018 were selected as subjects. According to the results of the drafting, these patients were divided into observation group and control group. The control group received salbutamol aerosol inhalation treatment. Patients in the observation group were treated with salbutamol combined with budesonide inhalation, and the total efficacy was compared. The differences in clinical symptom relief between the groups were recorded and analyzed, and the incidence of adverse reactions was calculated. Re-sults The total therapeutic effect of the observation group was significantly higher than that of the control group( P<0.05). At the same time, the wheezing time disappeared(4.35±0.24) d, the cough symptom relief time(2.98±1.01) d, and the total hospital stay(8.44±0.36)d were significantly shorter than the control group(t=23.41, 7.89, 25.15, P<0.05). There was no statistically significant difference in the incidence of adverse drug reactions between the observation group and the control group( P>0.05). Conclusion Patients with chronic obstructive pulmonary disease receiving salbutamol combined with budesonide inhalation have better effects, can improve symptoms such as cough, shorten the length of hospital stay, and have fewer adverse reactions after administration. It is worthy of popularization and application.
引文
[1]郁智慧.布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病患者的临床效果[J].临床合理用药杂志,2017,10(32):39-40.
[2]牧坤,高莹慧,苗淑贤,等.布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].中国实用医药,2017,12(33):104-105.
[3]王馨平,亓占中,吴昭萍,等.布地奈德、异丙托溴铵联合沙丁胺醇治疗慢性阻塞性肺疾病急性发作期对患者肺功能和疗效的影响分析[J].吉林医学,2018,39(9):1712-1713.
[4]李艳,张琼,张红,等.布地奈德分别联合异丙托溴铵和沙丁胺醇治疗慢性阻塞性肺疾病患者的影响[J].吉林医学,2019,40(1):79-80.
[5]王永松.布地奈德联合沙丁胺醇雾化吸入治疗全麻术中慢性阻塞性肺疾病患者急性发作效果观察[J].中外医学研究,2019,17(1):26-28.
[6]彭慧群,林伟革,何敏红,等.布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病急性加重期的效果[J].中国当代医药,2018,25(21):31-33.
[7]付丑春.布地奈德雾化液雾化吸入联合选择性β2-受体激动剂对慢性阻塞性肺疾病急性加重期患者血气指标的影响[J].吉林医学,2018,39(4):687-688.
[8]杨兰.布地奈德和沙丁胺醇联合雾化吸入治疗COPD急性发作期患者的临床疗效[J].实用临床医药杂志,2016,20(7):160-161.
[9]王沁,宋德胤.布地奈德联合沙丁胺醇雾化吸入治疗AECOPD的疗效及对肺功能相关指标的影响[J].实用临床医药杂志,2016,20(7):38-40,44.
[10]杨洪涛,陈哲,宋爱芹.雾化吸入布地奈德联合沙丁胺醇治疗慢性阻塞性肺疾病急性加重期的疗效及对肺功能相关指标的影响[J].实用临床医药杂志,2017,21(15):118-119,122.
[2]牧坤,高莹慧,苗淑贤,等.布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].中国实用医药,2017,12(33):104-105.
[3]王馨平,亓占中,吴昭萍,等.布地奈德、异丙托溴铵联合沙丁胺醇治疗慢性阻塞性肺疾病急性发作期对患者肺功能和疗效的影响分析[J].吉林医学,2018,39(9):1712-1713.
[4]李艳,张琼,张红,等.布地奈德分别联合异丙托溴铵和沙丁胺醇治疗慢性阻塞性肺疾病患者的影响[J].吉林医学,2019,40(1):79-80.
[5]王永松.布地奈德联合沙丁胺醇雾化吸入治疗全麻术中慢性阻塞性肺疾病患者急性发作效果观察[J].中外医学研究,2019,17(1):26-28.
[6]彭慧群,林伟革,何敏红,等.布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病急性加重期的效果[J].中国当代医药,2018,25(21):31-33.
[7]付丑春.布地奈德雾化液雾化吸入联合选择性β2-受体激动剂对慢性阻塞性肺疾病急性加重期患者血气指标的影响[J].吉林医学,2018,39(4):687-688.
[8]杨兰.布地奈德和沙丁胺醇联合雾化吸入治疗COPD急性发作期患者的临床疗效[J].实用临床医药杂志,2016,20(7):160-161.
[9]王沁,宋德胤.布地奈德联合沙丁胺醇雾化吸入治疗AECOPD的疗效及对肺功能相关指标的影响[J].实用临床医药杂志,2016,20(7):38-40,44.
[10]杨洪涛,陈哲,宋爱芹.雾化吸入布地奈德联合沙丁胺醇治疗慢性阻塞性肺疾病急性加重期的疗效及对肺功能相关指标的影响[J].实用临床医药杂志,2017,21(15):118-119,122.